Thibodeau Alexa, Nallasamy Nambi
Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Int Med Case Rep J. 2021 Oct 1;14:707-709. doi: 10.2147/IMCRJ.S324394. eCollection 2021.
Enfortumab vedotin is an antibody-drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient's presentation may reflect the first report of an undocumented adverse effect of this novel agent.
安维汀是一种抗体药物偶联物，最近获得了美国食品药品监督管理局的加速批准，用于治疗局部晚期或转移性尿路上皮癌。早期临床试验发现视力模糊、泪液增多以及其他与干眼症相关的症状可能是潜在的副作用。我们报告了一例在开始使用安维汀后发生双侧前囊下白内障的病例。此前并不知晓安维汀会导致白内障的发生或进展，因此，我们患者的情况可能反映了这种新型药物一种未记录的不良反应的首次报告。
